-
Post date
June 29, 2022
-
Posted by
Kieran Robertson
-
Posted in
Ecstasy, Health Canada approval, Health Canada restricted drug amendments, Mushrooms, OPTI.C, Optimi, Optimi Health, Optimi Health Corp., psilocybin, psychedelic assisted therapy, psychedelic drug market, Psychedelics, SABI Mind, SAP, Special Access Program
-
Post date
June 29, 2022
-
Posted by
Kieran Robertson
-
Posted in
Ecstasy, Health Canada approval, Health Canada restricted drug amendments, Mushrooms, OPTI.C, Optimi, Optimi Health, Optimi Health Corp., psilocybin, psychedelic assisted therapy, psychedelic drug market, Psychedelics, SABI Mind, SAP, Special Access Program
-
Post date
March 18, 2022
-
Posted by
Kieran Robertson
-
Posted in
best psychedelics companies, best psychedelics stocks, Canadian psychedelics companies, Canadian psychedelics market, clinical trials psychedelics, Dealer's License, Health Canada approval, licensed dealer, medical psychedelics, mushroom, mushroom formulation, mushroom laws, mushroom legalization, mushroom market, mushroom markets, mushroom research, mushroom stocks, Mushrooms, natural psychedelics, OPTI.C, Optimi, Optimi Health, Optimi Health Corp., psilocybin mushrooms, Psychedelics, psychedelics stocks 2022
-
Post date
March 18, 2022
-
Posted by
Kieran Robertson
-
Posted in
best psychedelics companies, best psychedelics stocks, Canadian psychedelics companies, Canadian psychedelics market, clinical trials psychedelics, Dealer's License, Health Canada approval, licensed dealer, medical psychedelics, mushroom, mushroom formulation, mushroom laws, mushroom legalization, mushroom market, mushroom markets, mushroom research, mushroom stocks, Mushrooms, natural psychedelics, OPTI.C, Optimi, Optimi Health, Optimi Health Corp., psilocybin mushrooms, Psychedelics, psychedelics stocks 2022
